Composition for treatment of aesthenopia
Inventors
Wada, Tatsuya • Mano, Takashi • Tanouchi, Masatoshi
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8663716-B2
Publication Date
2014-03-04
Expiration Date
Abstract
This is to provide a novel medicine and a food and a drink composition for treating aesthenopia excellent in improved effect of aesthenopia.The composition for the treatment of aesthenopia comprises chondroitin sulfate or a salt thereof.
Core Innovation
The invention relates to compositions for treating aesthenopia by orally administering salmon chondroitin sulfate or a salt thereof. The composition is provided as a medicine and/or as a food and drink composition, and the treatment is directed to a human suffering from aesthenopia.
In addition to salmon chondroitin sulfate, the oral administration includes one or more additional components selected from astaxanthin, lutein, blueberry extract, marigold extract, docosahexaenoic acid, hyaluronic acid, and mixtures thereof. The document states that combining salmon chondroitin sulfate with at least one eye-health ingredient strengthens the therapeutic effect.
The document includes background regarding the relation of glycosaminoglycan and aggrecan to the cornea and retina and discusses the use of the compositions in treating subjective eye symptoms and objective visual and VDT-related measures. Utility test outcomes are described after oral intake of salmon-derived chondroitin sulfate compositions, reporting significant improvements in symptoms and measures associated with eye fatigue, dryness, dimming, congestion, and flickering.
Claims Coverage
The independent claim is directed to a method of treating a human suffering from aesthenopia using oral administration of salmon chondroitin sulfate or a salt with one or more specified additional components. The claim contains 1 core inventive combination element.
Oral treating aesthenopia with salmon chondroitin sulfate and selected eye-health components
Treating a human suffering from aesthenopia by orally administering a therapeutically effective amount of salmon chondroitin sulfate or a salt thereof together with one or more additional components selected from astaxanthin, lutein, blueberry extract, marigold extract, docosahexaenoic acid, hyaluronic acid, and mixtures thereof.
Overall, the claim coverage centers on oral treatment of aesthenopia using salmon chondroitin sulfate or a salt combined with one or more selected components as the main inventive feature.
Stated Advantages
Significant improvement in subjective eye symptoms after oral intake of salmon-derived chondroitin sulfate compositions.
Significant improvement in objective visual and VDT-related measures after oral intake of salmon-derived chondroitin sulfate compositions.
Strengthened therapeutic effect by combining salmon chondroitin sulfate with at least one eye-health ingredient.
Documented Applications
Treating a human suffering from aesthenopia using oral administration of salmon chondroitin sulfate or a salt with specified additional eye-health ingredients.
Interested in licensing this patent?